
Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with a market capitalization of over $50 billion.
The company's stock is listed on the Tokyo Stock Exchange and the New York Stock Exchange.
In 2020, Takeda's revenue reached $18.2 billion, with a net income of $3.5 billion.
Takeda has a diverse portfolio of products, including vaccines, oncology treatments, and gastrointestinal medications.
The company has a strong presence in Asia, with a significant market share in Japan and other countries in the region.
Takeda's financial performance has been impacted by the COVID-19 pandemic, with a decline in revenue in 2020 compared to the previous year.
For your interest: Financial Information EXchange
Financial Performance
Takeda Pharmaceutical's financial performance is a key aspect to consider when evaluating the stock. The company's current financial strength is reflected in its cash-to-debt ratio of 0.18, indicating a relatively low level of liquidity.
The equity-to-asset ratio of 0.48 suggests that Takeda Pharmaceutical has a moderate level of equity in relation to its assets, which may indicate a balance between asset utilization and financial risk.
You might like: Rail First Asset Management
A Debt-to-EBITDA ratio of 4.09 indicates that Takeda Pharmaceutical's debt is relatively high compared to its earnings before interest, taxes, depreciation, and amortization (EBITDA). This may be a concern for investors.
Here's a summary of Takeda Pharmaceutical's key financial ratios:
Takeda Pharmaceutical's Piotroski F-Score of 7/9 suggests that the company has a high level of financial health, indicating a strong balance sheet and positive operating characteristics.
Takeda Pharmaceutical Estimates
Takeda Pharmaceutical Estimates are a crucial aspect of understanding the company's financial performance. According to the estimates, Takeda Pharmaceutical's revenue is expected to reach $29,252 in 2025, with a projected growth rate of 0.26% from the previous year.
The estimates also suggest that the company's dividend yield will be around 4.77% in 2025, with a dividend payout of $0.64 per share. This is a relatively stable figure, indicating that the company is committed to returning value to its shareholders.
Takeda Pharmaceutical's earnings per share (EPS) is expected to be around $0.26 in 2025, with a projected growth rate of 45% from the previous year. This is a significant increase, indicating that the company is expected to perform well in the coming years.
Here is a summary of the estimated financial metrics for Takeda Pharmaceutical:
These estimates provide a snapshot of Takeda Pharmaceutical's expected financial performance, and can be used as a guide for investors and analysts looking to make informed decisions.
Cost of Capital and Market Valuation
Takeda's management constantly assesses the Company's cost of capital, profitability, and market valuation using various metrics relevant to their business.
Takeda's profitability on a reported basis is significantly impacted by non-core/non-cash items, such as amortization of acquired intangible assets, as is the case with many other global pharmaceutical companies.
Takeda does not provide detailed forecasts other than single-year management guidance and financial forecasts, and descriptive goals for mid-to-long term revenue and profitability.
Their focus is on delivering growth through investment in their product portfolio, R&D, and business development, alongside a commitment to competitive total shareholder returns, which they believe will result in a competitive market valuation in the mid-to-long term.
Discover more: How Does Information Technology Affect Business
Financial Strength
Financial Strength is a critical aspect of a company's overall financial performance. A company with strong financials is better equipped to weather economic storms and achieve long-term growth.
The company's Cash-To-Debt ratio is a mere 0.18, which is a concern. This indicates that the company relies heavily on debt to fund its operations.
See what others are reading: Is Preferred Stock Debt or Equity
The Equity-to-Asset ratio is 0.48, which is relatively low. This means that the company's assets are largely financed by debt.
The Debt-to-Equity ratio is a staggering 0.73, indicating that the company's assets are heavily leveraged. This can make the company vulnerable to interest rate increases and economic downturns.
Debt-to-EBITDA ratio is 4.09, which is higher than the industry average. This suggests that the company's debt burden is significant.
The Interest Coverage ratio is 3.36, which is a positive sign. This indicates that the company's earnings are sufficient to cover its interest expenses.
The Piotroski F-Score is 7/9, indicating a relatively high level of financial health. However, the Altman Z-Score is 1.11, which suggests that the company is in a state of distress.
The Beneish M-Score is -2.74, indicating that the company is not a potential earnings manipulator. This is a positive sign, as it suggests that the company's financial statements are reliable.
Here's an interesting read: Why Is My Fico Score so Low
Dividend and Events
Takeda Pharmaceutical has a history of paying dividends, with a progressive dividend policy that aims to increase or maintain the annual dividend per share each year.
In FY2024, Takeda plans to return cash to shareholders with an annual dividend of 196 yen per ordinary share, consisting of interim and fiscal year-end dividends of 98 yen per share.
Takeda Pharmaceutical also distributes dividends twice a year.
Here's a breakdown of Takeda's dividend history:
The company also has a history of releasing earnings reports, with the most recent one being on January 30, 2024, where Takeda reported a revenue of 1.11 trillion yen and a net income of 105.755 billion yen in Q3 2024.
Takeda Pharmaceutical Events
Takeda Pharmaceutical has a history of releasing earnings reports, with the most recent one being for Q2 2024, which had an actual EPS of -0.106 USD.
Their earnings reports are usually released on a quarterly basis, with the Q1 2024 report showing an actual EPS of 0.209 USD.
Related reading: Credit Reports and Scores Answer Key
The company also holds Annual General Meetings, with the most recent one being on June 26, 2024, which had an actual EPS of 0.318 USD.
Here is a list of their upcoming earnings reports:
Takeda Pharmaceutical also has a calendar of upcoming events, which can be found in the Takeda Pharmaceutical Calendar section.
Shareholder Returns
Takeda Pharmaceutical has adopted a progressive dividend policy, aiming to increase or maintain the annual dividend per share each year.
The company distributes dividends twice a year, with an annual dividend of 196 yen per ordinary share in FY2024, consisting of interim and fiscal year-end dividends of 98 yen per share.
Takeda's dividend policy has been consistent over the years, with the company maintaining a strong commitment to returning value to its shareholders.
Here's a look at Takeda's dividend history:
Takeda's dividend yield has varied over the years, with a high of 4.58% in 2012 and a low of 2.50% in 2018.
Frequently Asked Questions
Is Takeda a good stock to buy?
Takeda Pharmaceutical has a high probability of beating the market in the next 3 months, making it a potentially good stock to buy. According to our analysis, it has a 9/10 AI Score, indicating a strong buy recommendation.
Is Takeda Pharmaceutical publicly traded?
Yes, Takeda Pharmaceutical is publicly traded, with its American Depositary Shares (ADS) listed on the New York Stock Exchange (NYSE).
What is the symbol for Takeda Pharmaceuticals?
The Takeda Pharmaceuticals symbol is a triangle representing the scales of a fish, symbolizing good luck and age/growth. This mark is rooted in Japanese culture, specifically the uroko, or fish scales.
Featured Images: pexels.com


